Qualigen Therapeutics Provides Corporate Update For Q3 And To Date 2023
Qualigen Therapeutics Provides Corporate Update For Q3 And To Date 2023
Qualigen Therapeutics提供2023年第三季度及迄今为止的公司最新情况
Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumors
Phase 1a patient recruitment ongoing; company anticipates sharing update on safety and preliminary efficacy in second quarter of 2024
Expect to select lead Pan-RAS inhibitor candidate for IND enabling studies in first quarter of 2024
在治疗晚期或转移性实体瘤的 QN-302 1 期临床试验的第一组中开始给三名患者给药
1a期患者招募正在进行中;公司预计将在2024年第二季度分享有关安全性和初步疗效的最新信息
预计将在2024年第一季度为IND支持研究选择潜在的Pan-ras抑制剂候选药物
CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation,today provides a corporate update for the third quarter ending September 30, 2023 and to date:
加利福尼亚州卡尔斯巴德,2023年11月14日(GLOBE NEWSWIRE)——一家临床阶段疗法公司Qualigen Therapeutics, Inc.(纳斯达克股票代码:QLGN),专注于开发有可能被指定为孤儿药的成人和儿科癌症的治疗方法,今天提供了截至2023年9月30日的第三季度及迄今为止的公司最新情况:
Highlights...
亮...
登录免费看全文
登录/注册